SAFC provides raw materials and process development services to establish the CHOZN series of cell lines to build therapeutic protein and monoclonal antibody manufacturing platform.
SAFC Cell Sciences and Development director Bruce Lehr said the CHOZN cell lines have complete traceability and are expected to enable customers to bring therapeutic candidates to market more quickly.
"The cell line has regulatory-friendly features that we believe will save time and money," Lehr said.
SAFC is also launching the CHOZN DHFR-/- CHO line for use in the production and manufacture of biological drugs.
The DHFR-/- CHO line is developed through CompoZr ZFN mediated gene editing of the dihydrofolate reductase (DHFR) locus in a characterized and fully documented CHO-K1 host.
The new CHOZN DHFR-/- CHO line allows process development scientists to use any common DHFR expression system for the selection and amplification in a fully traceable CHO-K1 background.